Siemens Healthineers AG

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Siemens Healthineers AG is a holding company that provides healthcare equipment, solutions, and services globally. It operates through the following business segments: Imaging, Diagnotics, Varian and Advanced Therapies. The Imaging segment provides imaging products, services, and solutions as well as digital offerings. The Diagnostics segment provides a broad array of testing applications, in the areas of laboratory, point of care and molecular diagnostics. The Varian segment provides innovative, multi-modality cancer care technologies based on integrated, advanced imaging, along with solutions and services to oncology departments in hospitals and clinics globally. The Advanced Therapies segment consist of integrated products, services and solutions across multiple clinical fields used in the treatment of diseases. Siemens Healthineers was founded on December 1, 2017 and is headquartered in Forchheim, Germany.

Siemens Healthineers AG (OTCPK:SEMHF) Q4 2024 Results Conference Call November 6, 2024 2:00 AM ET Company Participants Marc Koebernick - Head-Investor Relations Bernd Montag - Chief Executive Officer Jochen Schmitz - Chief Financial Officer Conference Call Participants Julien Dormois - Jefferies Hassan Al-Wakeel - Barclays David Adlington - JPMorgan Hugo Solvet - BNP Paribas Exane Graham Doyle - UBS Robert Davies - Morgan Stanley Dylan van Haaften - Stifel Operator Good morning, ladies and gentlemen, and welcome to Siemens Healthineers Conference Call. As a reminder, this conference is being recorded.

Siemens Healthineers AG (SEMHF) Q4 2024 Earnings Call Transcript

German medical technology company Siemens Healthineers reported a full-year adjusted earnings before interest and taxes (EBIT) and revenue growth in line with analysts' consensus on Wednesday.

Siemens Healthineers meets full-year earnings forecast

Siemens Healthineers is a company that I have written about a few times in the past, and I already have a bit of a position in SEMHF. My intention, before 4Q24, which is coming out in a few days, is to increase this stake. In this article, I show you why I intend to purchase more in Medtech and why I see a good upside here.

Siemens Healthineers: My Current Pick In Medtech Ahead Of Q4 2024

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Siemens Healthineers now offers Atellica Integrated Automation on the Atellica CI Analyzer,1 to consolidate 25 tasks typically handled manually by clinical laboratory staff. This offering redefines automation for clinical labs and has been shown to reduce the manual workflow steps laboratory professionals perform by 75%.2 Traditional total laboratory automation uses a track to transport patient samples throughout the laboratory to sample preparation equipment a.

Patient Testing Set to be Overhauled with Automation from Siemens Healthineers that Tackles Lab Workflow and Staffing Challenges

PALO ALTO, Calif.--(BUSINESS WIRE)-- #ASTRO24--Together with Siemens Healthineers, Varian Highlights Software and Imaging Innovations to Enable Personalized Patient Care at ASTRO 2024.

Together with Siemens Healthineers, Varian Highlights Software and Imaging Innovations to Enable Personalized Patient Care at ASTRO 2024

Novartis

Siemens Healthineers will pay more than 200 million euros ($223.8 million) to acquire the diagnostic arm of Advanced Accelerator Applications, owned by Novartis , the Financial Times reported on Saturday.

Siemens Healthineers to buy Novartis unit for over $223 million, FT reports

Siemens Healthineers AG (OTCPK:SEMHF) Q3 2024 Earnings Conference Call July 31, 2024 2:30 AM ET Company Participants Marc Koebernick - Head-Investor Relations Bernd Montag - Chief Executive Officer Jochen Schmitz - Chief Financial Officer Conference Call Participants Hassan Al-Wakeel - Barclays Veronika Dubajova - Citi David Adlington - JPMorgan Hugo Solvet - Exane Julien Dormois - Jefferies Julien Ouaddour - Bank of America Robert Davies - Morgan Stanley Sezgi Ozener - HSBC Operator Good morning, ladies and gentlemen, welcome to Siemens Healthineers Conference Call. As a reminder, this conference is being recorded.

Siemens Healthineers AG (SEMHF) Q3 2024 Earnings Call Transcript

German medical technology company Siemens Healthineers said on Wednesday its sales were hit by continued order delays in China in the third quarter, sending its shares more than 6% lower.

Siemens Healthineers hit by China order delays in Q3, but sees 2025 turnaround

CHICAGO--(BUSINESS WIRE)--ADLM 2024 Clinical Lab Expo--Siemens Healthineers has pushed the boundaries of medical engineering to improve patient care for more than 125 years. At the ADLM 2024 Clinical Lab Expo (from July 30-Aug. 1 at McCormick Place, Chicago, Booth #501), Siemens Healthineers will demonstrate what's achievable for laboratory testing with human-centered engineering and automation. New capabilities from Siemens Healthineers bring unmatched automation to laboratories of all sizes.

Human-Centered Engineering in the Lab Can Close the Distance Between Providers and Care: Siemens Healthineers to Exhibit How at ADLM 2024

Dublin, July 19, 2024 (GLOBE NEWSWIRE) -- The "AI in Medical Diagnostics Global Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.

AI in Medical Diagnostics Market Insights and Forecast, 2024-2033 - Top Ten Competitors Account for 56.02% of the Total Revenue, Led by Siemens Healthineers, Followed Closely by Merative L.P.

Siemens Healthineers reported good revenue growth and margin expansion in Q2 2024, with strong performance in Imaging, Varian, and Advanced Therapies segments. Despite a recent decline in share price, the company maintains a strong balance sheet and confirms full-year outlook for mid-to-high single-digit growth. Analysts have a positive outlook on Healthineers, with price targets ranging from €48 to €75/share and 18 out of 20 analysts recommending a "BUY" or outperform rating.

Siemens Healthineers: The Upside Is Clear To Me Over The Long Term

Healthcare capex demand has supported healthy order growth at Siemens Healthineers, as the company leverages new innovative platforms in Imaging (MRI, CT) and radiation oncology (Varian). The Street wants margin leverage and order growth in FQ3'24, and I think there's a good chance of getting both. Diagnostics still needs a lot of work to become more competitive, and a rumored sale/spin may be a better option.

Siemens Healthineers: Softer Orders A Risk, But The Story Remains Sound

Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Siemens Healthineers AG (SHL) - Product Pipeline Analysis, 2024 Update" company profile has been added to ResearchAndMarkets.com's offering. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Report Scope:

Siemens Healthineers (SHL) 2024 Product Pipeline Analysis and Ongoing Clinical Trails Insights

Siemens Healthineers AG (OTCPK:SEMHF) Q1 2024 Results Conference Call May 7, 2024 2:30 AM ET Company Participants Marc Koebernick - IR Bernhard Montag - CEO Jochen Schmitz - CFO Conference Call Participants Hassan Al-Wakeel - Barclays Veronika Dubajova - Citi Graham Doyle - UBS Sezgi Oezener - HSBC Julien Dormois - Jefferies Falko Friedrichs - Deutsche Bank Dylan van Haaften - Stifel Operator Good morning, ladies and gentlemen, and welcome to Siemens Healthineers Conference Call. As a reminder, this conference is being recorded.

Siemens Healthineers AG (SEMHF) Q1 2024 Earnings Call Transcript

German health technology company Siemens Healthineers reported on Tuesday second-quarter revenue growth slightly below consensus expectations, as it was hurt by declining revenue in China.

Siemens Healthineers Q2 revenue slightly misses expectations, faces headwinds in China

TAMPA, Fla.--(BUSINESS WIRE)--Enable Me, a VELA Medical company, today cited major new research by Siemens Healthineers entitled, “The future of Mammography: 4 critical challenges,” which cites poor workplace ergonomics and physical stress and strains as among the chief reasons for high radiologist turnover and fewer graduates entering the profession. The four critical challenges examined in the report include: Expand high-quality 3D mammography screening Limit inconclusive results and improve.

Enable Me Cites New Research by Siemens Healthineers Concluding Job-Related Physical Stresses and Strains for Radiologists Are Resulting in More Turnover and Fewer Entering the Profession

Siemens Healthineers has seen a 7.5% increase in its stock price since the last article and has a solid upside potential. The company's recent results show strong revenue growth, margin improvements, and successful contract wins. While the valuation of the company has increased, it still presents a potential double-digit annualized return for investors.

Siemens Healthineers: Good Return, Long-Term Potential Intact

Varian Medical Systems

German medical equipment maker Siemens Healthineers on Thursday posted first-quarter revenue above expectations and an operating result in line with consensus, driven by its U.S. cancer treatment unit Varian.

Siemens Healthineers Q1 sales beat expectations on strong Varian unit

Siemens Healthineers reported strong 4Q23 results with revenue growth of 11% and adjusted EBIT growth of 16%. The company aims to achieve double-digit EPS growth by 2025 and beyond through expansion in new areas and geographies. Despite a slight premium in valuation, the company has the potential to generate a significant rate of return for investors.

Siemens Healthineers: Strong Return, Still A 'Buy'

Siemens Healthineers AG (OTCPK:SEMHF) Q4 2023 Earnings Conference Call November 8, 2023 2:00 AM ET Company Participants Marc Koebernick - Investor Relations Bernd Montag - Chief Executive Officer Jochen Schmitz - Chief Financial Officer Conference Call Participants Graham Doyle - UBS Veronika Dubajova - Citi David Adlington - JPMorgan Hassan Al-Wakeel - Barclays Odysseas Manesiotis - Berenberg Robert Davies - Morgan Stanley Lisa Clive - Bernstein Richard Felton - Goldman Sachs Dylan van Haaften - Stifel Hugo Solvet - Exane Sezgi Ozener - HSBC Oliver Metzger - Oddo Falko Friedrichs - Deutsche Bank Operator Good morning, ladies and gentlemen, and welcome to Siemens Healthineers Conference Call. As a reminder, this conference is being recorded.

Siemens Healthineers AG (SEMHF) Q4 2023 Earnings Call Transcript

Siemens Healthineers on Wednesday posted better than expected fourth-quarter results helped by its cancer care unit and proposed an unchanged dividend for its fiscal year 2023.

Siemens Healthineers posts forecast beating Q4 results

Healthineers, a healthcare company formerly part of Siemens, offers potential market-beating upside. The company's main segments include imaging, diagnostics, advanced therapies, and Varian. Despite challenges from cost inflation and macro factors, Healthineers' solid company-wide results make it an appealing investment opportunity.

Siemens Healthineers: The Decline Makes The Upside Better

Siemens Healthineers AG (OTCPK:SEMHF) Q3 2023 Earnings Conference Call August 2, 2023 2:00 AM ET Company Participants Marc Koebernick - Head of Investor Relations Bernhard Montag - Chief Executive Officer Jochen Schmitz - Chief Financial Officer Conference Call Participants Hassan Al-Wakeel - Barclays Veronika Dubajova - Citi Graham Doyle - UBS David Adlington - JPMorgan Odysseas Manesiotis - Berenberg Robert Davies - Morgan Stanley Operator Good morning, ladies and gentlemen, and welcome to Siemens Healthineers Conference Call. As a reminder, this conference is being recorded.

Siemens Healthineers AG (SEMHF) Q3 2023 Earnings Call Transcript

U.S.-German medical device maker Siemens Healthineers on Wednesday reported a drop in quarterly operating profit and free cash flow due to the tailing-off of its rapid COVID-19 antigen test business.

Siemens Healthineers Q3 profit, cash flow fall on COVID test wind-up

TARRYTOWN, N.Y.--(BUSINESS WIRE)--The newest addition to the Siemens Healthineers Atellica in vitro diagnostics portfolio, the Atellica CI Analyzer1 for immunoassay and clinical chemistry testing, has received FDA clearance and is now available in many of the world's major markets. Labs operating at low to medium testing volumes will benefit from competitive advantages that the analyzer offers, including improved turnaround time predictability, advanced reporting functionality, and focused safe.

News for Siemens Healthineers AG Stock (SMMNY)